Department of Medicine, University of the Witwatersrand, Johannesburg Academic and Chris Hani/Baragwanath Hospitals, Johannesburg, South Africa.
Eur J Gastroenterol Hepatol. 2010 May;22(5):541-5. doi: 10.1097/MEG.0b013e3283344991.
An increased incidence of C-to-T1653 transversion (T1653) in the enhancer II region of the core promoter of hepatitis B virus has been reported in Japanese and Chinese patients with hepatocellular carcinoma infected with genotypes B or C of the virus, but little information is available in patients infected with other genotypes.
To document the prevalence of T1653 in Black Africans with hepatocellular carcinoma, in whom genotype A is the dominant genotype and subgenotype A1 the dominant subgenotype, and to correlate its presence with other core promoter mutations previously described in association with T1653.
The presence of the mutations was determined in 84 patients with hepatitis B virus-induced hepatocellular carcinoma and 50 matched asymptomatic carriers of the virus by extracting viral DNA from serum, amplification by polymerase chain reaction assay, and nucleotide sequencing.
T1653 was not found significantly more often in the cancer patients with genotype A and subgenotype A1 than in the controls. An association was found not only between T1653 and T1762, A1764 and dual T1762/A1764 in the patients with hepatocellular carcinoma, but also in the asymptomatic carriers.
T1653 mutation of hepatitis B virus does not occur more often in Black African patients with hepatocellular carcinoma with genotype A and subgenotype A1 than in asymptomatic carriers of the virus. No correlation specific to hepatocellular carcinoma was found between T1653 and other core promoter mutations in these patients. The presence of the T1653 mutation did not influence the e antigen status of the patients.
在乙型肝炎病毒核心启动子增强子 II 区发生 C 到 T1653 颠换（T1653）的发生率增加已在日本和中国的乙型肝炎病毒感染的肝细胞癌患者中报道，但在感染其他基因型的患者中，信息很少。
记录 T1653 在感染基因型 A 为主且亚基因型 A1 为主的乙型肝炎病毒的肝细胞癌的黑种人中的流行率，并将其存在与以前与 T1653 相关联的其他核心启动子突变相关联。
通过从血清中提取病毒 DNA、聚合酶链反应测定和核苷酸测序，在 84 例乙型肝炎病毒诱导的肝细胞癌患者和 50 例匹配的无症状病毒携带者中确定突变的存在。
T1653 在基因型 A 和亚基因型 A1 的癌症患者中并不比对照组更频繁地发现。不仅在肝细胞癌患者中发现了 T1653 与 T1762、A1764 和双重 T1762/A1764 之间的关联，而且在无症状携带者中也发现了这种关联。
与病毒无症状携带者相比，基因型 A 和亚基因型 A1 的黑种人肝细胞癌患者中乙型肝炎病毒 T1653 突变的发生率并不更高。在这些患者中，T1653 与其他核心启动子突变之间未发现特定于肝细胞癌的相关性。T1653 突变的存在并未影响患者的 e 抗原状态。
